Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28912190 | 0.98 | ACHE (0.67) | ACHEMAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL128701 | 0.86 | MAPT (0.67) | ACHEMAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL11421548 | 0.83 | ACHE (0.52) | ACHEMAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL13906293 | 0.83 | ACHE (0.54) | ACHEMAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL29403877 | 0.82 | ACHE (1.00) | ACHEMAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL12518 | 0.82 | ACHE (1.00) | ACHEMAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL27985067 | 0.81 | ACHE (0.52) | ACHEMAPTL3MBTL1HPGDALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27765317 | 0.80 | ACHE (0.95) | ACHEMAPTL3MBTL1HPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL27523444 | 0.80 | ACHE (0.95) | ACHEMAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL10269448 | 0.80 | AR (0.54) | ACHEMAPTL3MBTL1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 680 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109896919-A | A kind of method that photocatalysis one-step method prepares Bibenzyl compound | 中国科学院大连化学物理研究所 | 2019-06-18 | — | — | CN | claimed |
| CN-108947015-A | A kind of heavy metal-polluted method for treating water and its processing system | 李海霞 | 2018-12-07 | — | — | CN | claimed |
| CN-105668766-B | Heavy-metal ion removal equipment and its minimizing technology in a kind of trade effluent | 徐州工程学院 | 2018-02-02 | — | — | CN | claimed |
| CN-105668766-A | Device and method for removing heavy metal ions in industrial sewage | 徐州工程学院 | 2016-06-15 | — | — | CN | claimed |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-05 | — | — | US | claimed |
| JP-2004527459-A | — | — | 2004-09-09 | — | — | JP | claimed |
| US-20030225128-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BI YINGZHI (US) | 2003-12-04 | — | — | US | claimed |
| US-20020177587-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-28 | — | — | US | claimed |
| WO-2002020489-A2 | QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-14 | — | — | WO | claimed |
| CN-1253502-A | Method for preventing cardiovascular diseases using cyclooxygenase-2 inhibitor | SEARLE & CO (US) | 2000-05-17 | — | — | CN | claimed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| CN-1077588-A | The agricultural chemicals, insecticide, the acaricidal nematicidal agent composition that contain novel silane derivs | HOECHST AG (DE) | 1993-10-27 | — | — | CN | disclosed |
| US-4728669-A | PHYTOPHTHORA AND PLASMOPARA | CHEVRON RESEARCH COMPANY (US) | 1988-03-01 | — | — | US | disclosed |
| US-4440780-A | Fungicidal 3-(N-acyl-N-arylamino)-and 3-(N-thionoacyl-N-arylamino)-gamma-butyrolactones and gamma-thiobutyrolactones | CHEVRON RESEARCH COMPANY (US) | 1984-04-03 | — | — | US | disclosed |
| US-4407817-A | Fungicidal 3-(N-acyl-N-arylamino)- and 3-(N-thionoacyl-N-arylamino)-gamma-butyrolactones and gamma-thiobutyrolactones | CHEVRON RESEARCH COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| US-4241078-A | Fungicidal 3-(N-acyl-N-arylamino)-gamma-butyrolactones and gamma-butyrothiolactones | CHEVRON RESEARCH COMPANY (US) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | ACHE 4824/4885MAPT 4671/4885L3MBTL1 113/4885 |
| US-20030225128-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | ACHE 319/4885MAPT 4486/4885L3MBTL1 3529/4885 |
| US-20020177587-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE2A, PDE3A | ACHE 214/4885MAPT 4376/4885L3MBTL1 3080/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | ACHE 3993/4885MAPT 3674/4885L3MBTL1 3936/4885 |
| US-20070155775-A1 | Quinoline Inhibitors of cGMP Phosphodiesterase | PDE5A, PDE3A, PDE2A | ACHE 129/4885MAPT 4301/4885L3MBTL1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.